Skip to content

OCVC-BIF

Comparison of Drug-Coated versus Conventional Balloons for the Side Branch of the Bifurcation Lesion - MULTICENTER RANDOMIZED CONTROLLED STUDY -

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs052200077
Enrollment
300
Registered
2020-10-28
Start date
2020-11-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stable coronary artery disease coronary bifurcation lesion

Interventions

Subject: Patients undergoing initial PCI in bifurcation lesion of the native coronary artery which is intended to be treated with DES implantation in only main branch followed by kissing balloon infla
Drug-coated balloon

Sponsors

Sakata Yasushi
Lead Sponsor
Ishihara Takayuki
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who satisfy all of the following inclusion criteria and none of the exclusion criteria are enrolled in the present study. 1. Patients aged at least 20 years at the time of their consent 2. Patients who agree to be enrolled in the study giving signed written informed consent 3. Patients undergoing a first-time PCI in bifurcation 4. Patients undergoing PCI in bifurcation with a side branch 2.0-3.0 mm in diameter 5. Patients undergoing PCI in bifurcation which is intended to be treated with a single stenting strategy (DES implantation in only main branch) 6. Patients who can receive dual antiplatelet therapy according to the latest guideline 7. Patients who agree to receive coronary angiography 9 months after PCI

Exclusion criteria

Exclusion criteria: Patients are excluded from this study if they have the following criteria. 1. Patients who are pregnant or breast-feeding 2. In-stent restenosis 3. Lesion in the bypass graft 4. Lesion with acute coronary syndrome 5. Patients who developed acute myocardial infarction within 1 month 6. Patients complicated with active bleeding 7. Patients who are participating in intervention study, or who are participating or are scheduled to participate in clinical trial or clinical study with intervention before the end of the follow-up of the present study 8. Life expectancy within 1 year 9. Hemodialysis 10. Lesion with total occlusion 11. Patients who are judged as inappropriate subjects for the present study by the principal investigator or collaborators

Design outcomes

Primary

MeasureTime frame
Restenosis rate of side branch evaluated by QCA 9 months after PCI

Secondary

MeasureTime frame
1. Diameter stenosis of side branch by QCA 9 months after PCI 2. Revascularization rate of side branch 12 month after PCI 3. Procedure success rate 4. Procedure-related complication rate 5. Clinical outcomes 12 months after PCI: Major adverse cardiac event (defined as a composite of cardiac death, acute myocardial infarction, target lesion revascularization, stent thrombosis), cardiac death, acute myocardial infarction, target lesion revascularization, stent thrombosis 6. Late lumen loss of side branch ostium by OCT from immediately after PCI to 9 months after PCI 7. Late lumen loss volume of side branch by OCT from immediately after PCI to 9 months after PCI 8. Frequency of malapposed struts 9 months after PCI 9. Frequency of uncovered struts 9 months after PCI 10. Malapposition volume 9 months after PCI 11. Incidence of thrombus attachment 9 months after PCI

Contacts

Public ContactYohei Sotomi

The University of Osaka Hospital

ocvc-core@cardiology.med.osaka-u.ac.jp+81-3-5418-7428

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Aug 4, 2026